UPDATE : Tuesday, August 4, 2020
Celltrion Healthcare’s 2019 sales top ₩1 trillion
  • By Lee Han-soo
  • Published 2020.03.06 17:31
  • Updated 2020.03.06 17:31
  • comments 0

Celltrion Healthcare said that it registered 1 trillion won ($840.6 million) in sales last year, up 54 percent from 2018.

The company also recorded 82.8 billion won in operating profit, turning to a surplus from a deficit in 2018, and posted a net profit of 65 billion won, a drastic 470 percent increase over the cited period.

Celltrion headquarters in Incheon.

The company attributed its strong sales to the launch of Truxima in the U.S., stabilized prices in European markets, and strong global sales of its three major pipelines – Truxima, Herzuma, and Remsima.

"Truxima's sales in North America contributed significantly to improved profitability," the company said. "We launched Truxima in the United States last year, and its performance so far is encouraging."

Last month, Teva, the company's U.S. distribution partner, announced in its 2019 report that the biosimilar achieved double-digit market share in the U.S. in the fourth quarter of last year.

This year, Celltrion Healthcare said, it will continue to grow by launching Remsima SC, the world's first infliximab subcutaneous injection drug, and expanding the sales of Truxima and Herzuma in the U.S., as well as lifting its market share in Japan, Canada, and Latin America.

"Remsima SC, which was launched in Germany in February, has already started to be prescribed there," the company said. "We will launch the product in major European countries such as the U.K. and the Netherlands."

Encouraged by the successful completion of renegotiation with global partners, which have been going on since 2018, Celltrion Healthcare also plans to sell Remsima IV and Remsima SC directly in primary European markets, improving its profitability further, the company added.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top